Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) insider Marinus Verwijs sold 1,981 shares of the business's stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $21.02, for a total value of $41,640.62. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Marinus Verwijs also recently made the following trade(s):
- On Tuesday, March 19th, Marinus Verwijs sold 5,300 shares of Aerovate Therapeutics stock. The stock was sold at an average price of $26.08, for a total transaction of $138,224.00.
Aerovate Therapeutics Trading Down 2.2 %
Shares of Aerovate Therapeutics stock opened at $20.29 on Friday. The business has a 50-day moving average price of $24.72 and a two-hundred day moving average price of $19.76. Aerovate Therapeutics, Inc. has a 1-year low of $9.41 and a 1-year high of $32.42.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its earnings results on Monday, March 25th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.06). On average, sell-side analysts forecast that Aerovate Therapeutics, Inc. will post -2.78 earnings per share for the current year.
Institutional Inflows and Outflows
Elon’s New Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
A number of institutional investors have recently modified their holdings of AVTE. Alps Advisors Inc. raised its stake in Aerovate Therapeutics by 11.3% during the 3rd quarter. Alps Advisors Inc. now owns 20,395 shares of the company's stock worth $277,000 after buying an additional 2,075 shares during the period. Swiss National Bank grew its stake in Aerovate Therapeutics by 30.9% in the third quarter. Swiss National Bank now owns 21,201 shares of the company's stock valued at $288,000 after acquiring an additional 5,000 shares during the period. Eventide Asset Management LLC bought a new stake in shares of Aerovate Therapeutics during the fourth quarter valued at approximately $276,000. Silverarc Capital Management LLC acquired a new position in shares of Aerovate Therapeutics during the third quarter worth approximately $1,357,000. Finally, Vestal Point Capital LP acquired a new position in shares of Aerovate Therapeutics during the fourth quarter worth approximately $9,052,000.
Analyst Ratings Changes
A number of equities analysts have recently commented on AVTE shares. Wells Fargo & Company reiterated an "overweight" rating and set a $35.00 price target on shares of Aerovate Therapeutics in a report on Monday, April 1st. Wedbush reiterated an "outperform" rating on shares of Aerovate Therapeutics in a research report on Thursday, April 4th. Finally, Jefferies Financial Group began coverage on Aerovate Therapeutics in a research note on Monday, March 25th. They issued a "buy" rating and a $65.00 price target for the company.
Read Our Latest Analysis on Aerovate Therapeutics
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
